Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Recs

6
Player Avatar zzlangerhans (99.75) Submitted: 6/11/2011 12:43:35 AM : Outperform Start Price: $14.74 AMRN Score: -66.67

Amarin had their own little flash crash today after some remarks by the CEO that indicated he wasn't dying to unload the company immediately. It was the latest in a series of statements that have shaken out short-term momentum traders and buyout speculators since the share price hit 19.5 a couple of weeks ago. Today the share price dropped two points in just minutes before regaining most of the losses over the rest of the day. I wonder if the Savient situation is what's making people so nervous. But is it rational to expect a buyout before the AMR101 NDA is even submitted? When was the last time that happened? A partnership seems much more likely at this time anyway.

I'm surprised to see Amarin in this position at all. I'll never understand why the company flirted with bankruptcy after years of failed trials of AMR101 in Huntington's, Parkinson's, and niacin flush before addressing the more obvious indication of hypertriglyceridemia. But after strongly positive results from two phase III trials, FDA approval seems highly likely. Partnership, buyout, or not I believe Amarin will rise back towards 20 once the NDA process is underway.

Member Avatar Ashelimited (80.61) Submitted: 7/15/2011 1:58:36 PM
Recs: 0

ZZ,

I am also optimistic about AMRN's chances to head back toward 20, and I think the current levels (13.60) offer an even better buying opportunity. However, I was wondering what you thought about the new patent worries that may be driving the pps down, as well as the prospect that AMRN may have to do a small dilution (raise cash) to finance a CV outcomes study. What is your take on the situation? Are you still long and strong AMRN?

Garrett

Featured Broker Partners


Advertisement